Case Report: Primary Immunodeficiencies, Massive EBV+ T-Cell Lymphoproliferation Leading to the Diagnosis of ICF2 Syndrome

Gonçalo Luzes Padeira1, Catarina Araújo2, Ana Isabel Cordeiro1, João Freixo3, Catarina Gregório Martins4,5 and João Farela Neves1,4,5*

1 Hospital de Dona Estefânia, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal, 2 Departamento de Anatomia Patológica, Centro Hospitalar Universitário de Lisboa Central, Lisbon, Portugal, 3 Centro de Genética Preditiva e Preventiva, Instituto de Biologia Molecular e Celular, Instituto de Investigação e Inovação em Saúde, Porto, Portugal, 4 CEDOC, Chronic Diseases Research Center, NOVA Medical School, Lisbon, Portugal, 5 Comprehensive Health Research Centre (CHRC), NOVA Medical School, Nova University of Lisbon, Lisbon, Portugal

In immunocompromised patients, EBV may elicit B-cell transformation and proliferation. A 5-year-old microcephalic boy was admitted with fever and non-malignant polymorphic T-cell lymphoproliferative disease associated with EBV. A presumptive diagnosis of primary immunodeficiency with inability to control EBV was made and next-generation sequencing led to the identification of a novel ZBTB24 mutation (ICF2-syndrome). This case shows that susceptibility to EBV seems to be particular of ICF-2 as it has not been described in the other types of ICF. It is mandatory to raise the hypothesis of an underlying PID in case of severe EBV infection.

Keywords: case report, ICF-2, Primary immune deficiencies, EBV, lymphoproliferation

INTRODUCTION

Epstein-Barr virus (EBV) is one of eight human herpesviruses that establishes lifelong persistent infection in humans. More than 90% of adults have been infected with EBV, whose life cycle mimics the natural differentiation pathway of B cells, giving the virus access to its site of latent infection, the resting memory B cells (1).

Primary infection in early childhood is generally asymptomatic but later in life it usually causes infectious mononucleosis. In some patients, EBV can induce lymphoproliferation, lymphoma, and hemophagocytic lymphohistiocytosis (HLH) particularly in immunocompromised patients, reflecting the importance of continuous immune surveillance for the regulation of the virus (2). In healthy patients the propensity of EBV to induce B-cell proliferation seems to be counterbalanced by an immune system that maintains the overall number of EBV-infected B lymphocytes in a steady level (2).

After infecting B-cells (and epithelial cells), the EBV replicative cycle that follows results in the expression of lytic proteins involved in immune evasion which interfere with antigen (Ag) processing and presentation to CD8+ T-cells. Then, EBV switches to latent infection of B cells avoiding T-cell and NK-cell immunity, which is critical for colonization of the host. Although the exact mechanisms are still being discussed latency can take several forms (2), starting as a growth-
transferring latent infection of B cells where expression of all latent proteins (EBV nuclear Ags (EBNA) 1, 2, 3A, 3B, 3C, and LMP; latent membrane proteins (LMPs) 1 and 2) can be detected. In this state infected B cells expand rapidly in extrafollicular areas of oropharyngeal lymphoid tissues such as the tonsils, and large numbers of infected B cells can be found in the blood (latency III). Most of these infected cells are cleared by the immune system (2). Other latency forms consist of latency II which is a more restrict form of latency design to evade the immune system and where only EBNA1 and LMPs are expressed. Finally, only EBNA1 is expressed in latency I. In fact, viral persistence is achieved largely through silent infection of memory B cells where expression of viral Ags is extinguished (latency 0); in healthy carriers, EBV is exclusively found within this population in the blood (2).

Primary immunodeficiencies that present with EBV-driven LPDs are related to defects in the growth, differentiation and activities of B and/or T cells. Briefly, the host defense to EBV can be compromised by germline mutations in genes that encode proteins that are crucial for an adequate response (3): a) in the initial interaction between EBV-infected or antigen-presenting B cells and CD8+ T cells (CD27/CD70, 4-1BB/4-1BBL) and downstream signaling (requiring MAGT1, ITK, and RasGRP1) that will induce DNA synthesis by activation of CTPS1 and elicit proliferation of EBV-specific CD8+ T cells; b) or following expansion of EBV-specific CD8+ T cells by compromising cytotoxicity of CD8+ T and NK cells as seen in patients with mutations in the SAP pathway. SAP links SLAM-family receptors on hematopoietic cells with downstream intracellular signaling pathways to regulate T and NK cells. In the absence of SAP, cytotoxic functions of CD8+ T and NK cells induced by engaging the SLAM-family receptors 2B4 (CD244) and NTB-A are abolished. These two pathways are required for the functioning of one-another as illustrated by the ASGRP1-dependent induction of CTPS1, the impaired NKGD2 and 2B4 expression secondary to CD27/CD70 deficiency or by the impaired PLCγ1 activation due to ITK or MAGT1 deficiency (3).

Moreover, in immunocompromised patients who present an impaired defense against EBV, the virus may elicit cell transformation and proliferation, leading to EBV-induced lymphoproliferative disorders (EBV-LPDs) (2). These are usually divided in reactive proliferations (including reactive lesions with no malignant potential like infectious mononucleosis and reactive lesions with varied malignant potential), B cell proliferations (including Hodgkin lymphoma and plasma cell neoplasms), T/natural killer (NK)-cell proliferations and immunodeficiency-related lymphoid proliferations. Combined T-cell and B-cell immunodeficiencies account for about two thirds of PIDs associated with EBV-driven lymphoproliferative disorders (4).

There are several primary immunodeficiencies in which EBV+B-cell LPDs are an important feature, but very few germline mutations have been associated to documented EBV+ T/NK-cell LPD (4). We report the case of a boy with massive EBV+ T-cell LPD caused by a novel homozygous ZTBZ24 mutation.

**CASE REPORT**

Five-year-old boy with no relevant family background but with personal history of epilepsy, severe psychomotor retardation, microcephaly, micrognathia, hypertelorism, low-set ears, epicanthal folds, and macroglossia (Figure 1A).

Admitted in the context of prolonged fever and generalized lymphadenopathies (cervical, abdominal, and mediastinal). He had no other complaints.

An extensive investigation was performed and an elevated EBV viral load (50,000 copies/ml) despite a negative EBV serology was found. Prior to receiving any immunosuppressive treatment, immunologic evaluation was performed and revealed normal serum levels of IgG, IgA and IgM, normal responses to diptheria and tetanus and a severe T and NK-cell lymphopenia, as well as B-cell lymphopenia, particularly low post-germinal class-switched memory B cells (Table 1).

An excisional biopsy of a lymphadenopathy was suggestive of non-malignant polymorphic EBV (EBER+) T-cell lymphoproliferative disease. This lymphoproliferation was accompanied by infiltration of the digestive tract and he developed severe upper and lower digestive bleeding with two episodes of hemorrhagic shock, needing multiple blood transfusions. A gastric ulcer biopsy confirmed a polymorphic T infiltrate (EBER+) (Figure 1B) and rearrangements of T cell receptors and flow cytometry excluded monoclonality. Based on the presence of EBV-LPD in a patient with personal history of microcephaly and psychomotor retardation a presumptive diagnosis of primary immunodeficiency with inability to control EBV was made. He was treated with rituximab for lymphocyte depletion with resolution of fever and of the gastrointestinal bleeding, which were accompanied by marked decrease in the EBV viral load (viral load 50,000> 1015 copies/ml (Figure 1D). Hematopoietic stem cell transplantation (HSCT) was not proposed due to the personal history of severe psychomotor retardation.

Based on the pathologic findings of EBV+ T-cell LPD, and despite the absence of documented T-cell infection in the peripheral blood (5), cyclophosphamide was added to rituximab when the patient eventually presented a disease relapse, with fever, increasing viral load and generalized lymphadenopathies. This led to a dramatic clinical improvement and a decrease in viral load to 20 copies/ml (Figure 1D). Unfortunately, in the following months, the patient had several infectious episodes (namely central line related sepsis), leading to intermittent discontinuation of the immunosuppressive treatment and subsequent relapse of the disease with massive lymphoproliferation (Figure 1C) and increasing viral loads, eventually leading to his death.

A next-generation sequencing panel of EBV-susceptibility related genes (Table S1) led to the identification of a novel c.301G>A (p.(Ala101Thr)) homozygous ZBTB24 (NM_014797.2) mutation. This residue is highly conserved and there is a physicochemical difference between alanine and threonine (Table S2). This is a very rare variant and no homozygotes have been reported (total allele frequency of around 0.017%, 48 heterozygous; 0 homozygous). Most bioinformatics analysis predicted that the patient’s mutation Ala101Thr was damaging (e.g., SIFT =
deleterious; MutationTaster = disease causing), with a CADD score of 17.49. This led to the diagnosis of immunodeficiency, centromeric region instability and facial anomalies syndrome (ICF) type 2. Both parents were found to harbor a heterozygotic mutation which allowed family counseling. Unfortunately, the patient died before karyotyping could be performed. We performed post-mortem Southern blot analysis for SAT2/Alpha-Satellite repeat methylation but did not find the characteristic ICF-associated repeat DNA hypomethylation. This is probably explained by the unusual nature of the mutation: a homozygous missense variant in the BTB domain.

**DISCUSSION**

ICF is a rare autosomal recessive disorder caused by defective DNA methylation, with approximately 70 cases reported so far (4). Hypomethylation of satellite regions on chromosomes 1, 9,
TABLE 1 | Investigation.

| Infectious                  | Reference          |
|-----------------------------|--------------------|
| EBV-VCA IgM/IgG             | Negative/          |
| EBV-EA IgG                  | Negative           |
| EBV-EBNA IgG                | Negative           |
| CMV, HSV 1,HSV2, VZV, HHV6, HHV7 PCR | Negative/          |
| CMV IgM/IgG                | Negative/          |
| Enterovirus PCR in stools; Multiplex PCR for respiratory virus | Negative/          |
| Parvovirus IgG/IgM          | Negative/          |
| HIV 1 and 2                 | Negative/          |
| VHA IgM/IgG                 | Negative/          |
| Serology for Coxiella burnetti, Leishmania, Leptospiara, Mycoplasma, Toxoplasma | Negative/          |
| IGRA                        | Negative/          |
| Immunologic                 | Reference          |
| Immunoglobulin G (mg/dL)    | 580-1730 903       |
| Immunoglobulin A (mg/dL)    | 32-360 202         |
| Immunoglobulin M (mg/dL)    | 56-210 83          |
| Immunoglobulin E (KUVL)     | 0-90 10.2          |
| Lymphocyte populations      |                    |
| Abs value(cells/ul)         | 1.200-6850 550     |
| Lym B (CD19+ %)             | 6.1-25.2 10.58     |
| Lym B (CD19+ cells/ul)]     | 157-1637 58.2      |
| PreGerminal %               | 48-88 96.56       |
| PreGerminal(cells/ul)       | 70-1350 56.2       |
| PostGerminal %              | 8-33 3.44         |
| PostGerminal(cells/ul)      | 35-490 2          |
| Unswitched %                | 3-22 0.19         |
| Unswitched(cells/ul)        | 18-333 0.11       |
| Switched %                  | 2-17.4 3.26       |
| Switched(cells/ul)          | 14-200 1.9        |
| Lym T (CD3+ %)              | 55-97 80          |
| Lym T (CD3+ cells/ul)]      | 850-5300 490      |
| CD3+/CD4+ %                 | 26-61 71.27       |
| Naive %                     | 42-100 26.28      |
| Naive(cells/ul)             | 265-2900 103      |
| Central Memory %            | 1-100 71.43       |
| Central Memory(cells/ul)    | 150-800 280       |
| Effector Memory %           | 0.2-15 2.4        |
| Effector Memory(cells/ul)   | 9-222 9.4         |
| CD3+/CD8+ %                 | 13-47 13.8        |
| CD3+/CD8+ cells(ul)         | 188-1800 76.1     |
| Naive %                     | 16-100 46.39      |
| Naive(cells/ul)             | 94-1130 35.3      |
| Central Memory %            | 1-39 42.05        |
| Central Memory(cells/ul)    | 26-450 32         |
| Effector Memory %           | 0.4-100 1.45      |
| Effector Memory(cells/ul)   | 0-151 1           |
| Effector TD CD27+ %         | 0-38 0.17         |
| Effector TD CD27+(cells/ul) | 0-385 16.5        |
| Effector TD CD27- %         | 0.01-7.2 0.06     |
| Effector TD CD27-(cells/ul) | 1-735 2.2         |
| T TCRgd+ %                  | 2-24 3.37         |
| T TCRgd+(cells/ul)          | 44-748 16.5       |
| T TCRgd- %                  | 0.04-1.3 0.17     |
| T TCRgd-(cells/ul)          | 3-104 5.5         |
| NK CD3-/CD16 56+ %          | 2-31 0.27         |
| NK CD3-/CD16 56+ cells(ul)  | 106-1750 1.5      |

In bold values outside the reference range.
Finally, it is mandatory to raise the hypothesis of an underlying PID in case of severe EBV infection, as HSCT is the only curative treatment in many of these cases. When HSCT is not an available therapeutic option (as in this case) the approach to chronic EBV infection is extraordinarily complex and should be individualized. The experience in controlling EBV in immunosuppressed patients is based on post-transplant lymphoproliferative disorders (PTLD) experience, where the mainstay is reduction of immunosuppression, which is an impossibility in primary immunodeficiency recipients. When B cell depletion with rituximab does not lead to a long-lasting control of the disease, regimens used in lymphoma therapy, such as cyclophosphamide, vincristine and prednisone, have been used despite an unsatisfactory outcome in many of these patients (15).

In summary, we report a patient who succumbed to EBV-T-cell LPD that harbored a novel homozygous A101T mutation in the ZBTB24 gene, causing ICF2. Future studies [such as the luciferase assay described by Daxinger et al (16)] will hopefully help us describe how this mutation affects ZBTB24’s role in controlling expression of CDCA7. This adds to the 5 previously reported cases in the literature, and we discuss the complex approach to the treatment of these patients in the absence of putative curative treatment.

DATA AVAILABILITY STATEMENT

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding author.

REFERENCES

1. Yin H, Qu J, Peng Q, Gan R. Molecular Mechanisms of EBV-Driven Cell Cycle Progression and Oncogenesis. Med Microbiol Immunol (2019) 208(5):573–83. doi: 10.1007/s00430-018-0570-1
2. Tangye SG, Palendira U, Edwards ES. Human Immunity Against EBV-Related Hodgkin Lymphoma: Lessons From the Clinic. J Exp Med (2017) 214(2):269–83. doi: 10.1084/jem.20161846
3. Tangye SG, Latour S. Primary Immunodeficiencies Reveal the Molecular Requirements for Effective Host Defense Against EBV Infection. Blood (2020) 135(9):644–55. doi: 10.1182/blood.2019009928
4. Licciardi F, van den Boogaard M, Delle Piane M, Tovo PA, Montin D. Ebv-Related Hodgkin Lymphoma in an ICF2 Patient: is Ebv Susceptibility a Hallmark of This Icf Subtype? J Clin Immunol (2019) 39(3):234–6. doi: 10.1007/s10875-019-00596-6
5. Fournier B, Boutboul D, Bruneau J, Mot C, Boulanger C, Malphettes M, et al. Rapid Identification and Characterization of Infected Cells in Blood During Chronic Active Epstein-Barr Virus Infection. J Exp Med (2020) 217(11). doi: 10.1084/jem.20192262
6. Sogkas G, Dubrowsinskaja N, Bergmann AK, Lentes J, Ripperger T, Fedchenko M, et al. Progressive Immunodeficiency With Gradual Depletion of B and CD4⁺ T Cells in Immunodeficiency, Centromeric Instability and Facial Anomalies Syndrome 2 (Icf2). Dis (Basel Switzerland) (2019) 7(2):34. doi: 10.3390/diseases7020034
7. Thijssen PE, Ito Y, Grillo G, Wang J, Velasco G, Nitta H, et al. Mutations in CDCA7 and HELLS Cause Immunodeficiency-Centromeric Instability-Facial Anomalies Syndrome. Nat Commun (2015) 6:7870. doi: 10.1038/ncomms8870
8. Liang J, Yan R, Chen G, Feng J, Wu WW, Ren W, et al. Downregulation of ZBTB24 Hampers the G0/1- to S-Phase Cell-Cycle Transition Via Upregulating the Expression of IRF-4 in Human B Cells. Genes Immun (2017), 276–82. doi: 10.1038/gene.2016.18
9. Sterlin D, Velasco G, Moshous D, Touzot F, Mahlaoui N, Fischer A, et al. Genetic, Cellular and Clinical Features of ICF Syndrome: A French National Survey. J Clin Immunol (2016) 36:149–59. doi: 10.1007/s10875-016-0240-2
10. Kamae C, Imai K, Kato T, Okano T, Honma K, Nakagawa N, et al. Clinical and Immunological Characterization of ICF Syndrome in Japan. J Clin Immunol (2018) 38(8):927–37. doi: 10.1007/s10875-018-0559-y
11. Harnisch E, Buddingh EP, Thijssen PE, Brooks AS, Driessen GJ, Kerseboom R, et al. Hematopoietic Stem Cell Transplantation in a Patient With ICF2 Syndrome Presenting With EBV-Induced Hemophagocytic Lymphohistiocytosis. Transplantation (2016) 100:e35–6. doi: 10.1097/TP.0000000000001210
12. Burk CM, Coffey KE, Mace EM, Bostwick BL, Chinn IK, Coban-Akdemir ZH, et al. Immunodeficiency, Centromeric Instability, and Facial Anomalies (ICF) Syndrome With NK Dysfunction and EBV-Driven Malignancy Treated With Stem Cell Transplantation. J Allergy Clin Immunol In Pract (2020) 8(3):1103–6.e3. doi: 10.1016/j.jaip.2019.08.040
13. Schaefer BC, Strominger JL, Speck SH. Host-Cell-Determined Methylation of Specific Epstein-Barr Virus Promoters Regulates the Choice Between Distinct Viral Latency Programs. Mol Cell Biol (1997) 17(1):364–77. doi: 10.1128/MCB.17.1.364

ETHICS STATEMENT

Written informed consent was obtained from the minor(s)’ legal guardian/next of kin for the publication of any potentially identifiable images or data included in this article.

AUTHOR CONTRIBUTIONS

GP designed the study and wrote the paper. CA performed pathology analysis; AIC performed bibliographical research and was medical doctor of the patient; JF performed genetic analysis and reviewed the manuscript; CGM performed immunological analysis. JFN designed the study and analyzed the data. All authors contributed to the article and approved the submitted version.

FUNDING

The present publication was funded by Fundação Ciência e Tecnologia, IP national support through CHRC (UIDP/04923/2020).

SUPPLEMENTARY MATERIAL

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fimmu.2021.654167/full#supplementary-material
Conflict of Interest: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Copyright © 2021 Padeira, Araújo, Cordeiro, Freixo, Martins and Neves. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.